{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:20:58Z","timestamp":1790220058938,"version":"4.1.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,5,28]]},"abstract":"Importance<\/jats:title>Most people who smoke do not quit on their initial attempt.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Using a double-blind, placebo-controlled, sequential multiple assignment randomized trial, 490 volunteers were randomized to receive 6 weeks of varenicline or CNRT. After 6 weeks, nonabstainers were rerandomized to continue, switch, or increase medication dosage for 6 additional weeks. The study was conducted from June 2015 through October 2019 in a Texas tobacco treatment clinic.<\/jats:p><\/jats:sec>Interventions<\/jats:title>The initial treatment was 2 mg\/d of varenicline or the combined replacement therapy of a 21-mg patch plus 2-mg lozenge. The rerandomized participants either continued with their initial therapies, switched between varenicline and CNRT, or increased dosages either to 3-mg or more of varenicline or to a 42-mg patch and lozenges. All received weekly brief counseling.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Biochemically verified 7-day point prevalence abstinence at the end of treatment at 12 weeks.<\/jats:p><\/jats:sec>Results<\/jats:title>The 490 randomized participants (210 female [43%], 287 non-Hispanic White [58%], mean age, 48.1 years) smoked an average of 20 cigarettes per day. After the first phase, 54 participants in the CNRT group were abstinent and continued their therapy; of the 191 who were not abstinent, 151 were rerandomized, and the 40 who did not return for rerandomization were assigned to continue their initial CNRT condition in phase 2. The end-of-treatment abstinence rate for the 191 phase 1 nonabstainers was 8% (95% credible interval [CrI], 6% to 10%) for the 90 (47%) who continued at the dosage condition, 14% (CrI, 10% to 18%) for the 50 (33%) who increased their dosage, and 14% (95% CrI, 10% to 18%) for the 51 (34%) who switched to varenicline (absolute risk difference [RD], 6%; 95% CrI, 6% to 11%) with more than 99% posterior probability that either strategy conferred benefit over continuing the initial dosage. After the first phase, 88 participants in the varenicline group were abstinent and continued their therapy; of the 157 who were not abstinent, 122 were rerandomized and 35 who did not return for rerandomization were assigned to continue with the varenicline condition. The end-of-treatment abstinence rate for the 157 phase 1 nonabstainers was 20% (95% CrI, 16% to 26%) for the 39 (32%) who increased their varenicline dosage, 0 (95% CrI, 0 to 0) for the 41 (34%) who switched CNRT, and 3% (95% CrI, 1% to 4%) for the 77 (49%) who were assigned to the continued varenicline condition (absolute RD, \u22123%; 95% CrI, \u22124% to \u22121%) with more than 99% posterior probability that continuing varenicline at the initial dosage was worse than switching to a higher dosage. Furthermore, increasing the varenicline dosage had an absolute RD of 18% (95% CrI, 13% to 24%) and a more than 99% posterior probability of conferring benefit. The secondary outcome of continuous abstinence at 6 months indicated that only increased dosages of the CNRT and varenicline provided benefit over continuation of the initial treatment dosages.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>For individuals who smoked but did not achieve abstinence after treatment with varenicline, increasing the dosage enhanced abstinence vs continuing, whereas for nonabstainers initially treated with CNRT, a dosage increase or switch to varenicline enhanced abstinence and may be viable rescue strategies.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02271919<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2024.4183","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T15:32:47Z","timestamp":1714663967000},"page":"1722","source":"Crossref","is-referenced-by-count":13,"title":["Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement"],"prefix":"10.1001","volume":"331","author":[{"given":"Paul M.","family":"Cinciripini","sequence":"first","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Green","sequence":"additional","affiliation":[{"name":"Center for Clinical Research and Evidence-Based Medicine, Department of Pediatrics, University of Texas at Houston Health Sciences Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Shete","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Minnix","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokhun","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Clinical Research and Evidence-Based Medicine, Department of Pediatrics, University of Texas at Houston Health Sciences Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kypriotakis","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Beneventi","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice A.","family":"Blalock","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Versace","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Karam-Hage","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"52","key":"joi240036r3","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.15585\/mmwr.mm6552a1","article-title":"Quitting smoking among adults\u2014United States, 2000-2015.","volume":"65","author":"Babb","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"45","key":"joi240036r4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.15585\/mmwr.mm6845a2","article-title":"Tobacco product use and cessation indicators among adults\u2014United States, 2018.","volume":"68","author":"Creamer","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"joi240036r6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011045","article-title":"Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers.","volume":"6","author":"Chaiton","year":"2016","journal-title":"BMJ Open"},{"issue":"10","key":"joi240036r7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/sim.v24:10","article-title":"An experimental design for the development of adaptive treatment strategies.","volume":"24","author":"Murphy","year":"2005","journal-title":"Stat Med"},{"issue":"4","key":"joi240036r8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1037\/a0029372","article-title":"Experimental design and primary data analysis methods for comparing adaptive interventions.","volume":"17","author":"Nahum-Shani","year":"2012","journal-title":"Psychol Methods"},{"issue":"2","key":"joi240036r9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/phar.2018.38.issue-2","article-title":"Current and emerging pharmacotherapies for cessation of tobacco smoking.","volume":"38","author":"G\u00f3mez-Coronado","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"4","key":"joi240036r10","article-title":"Antidepressants for smoking cessation.","volume":"4","author":"Howes","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"joi240036r11","doi-asserted-by":"publisher","first-page":"CD009329","DOI":"10.1002\/14651858.CD009329.pub2","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis.","volume":"2013","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"joi240036r12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/add.v117.4","article-title":"Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials.","volume":"117","author":"Thomas","year":"2022","journal-title":"Addiction"},{"issue":"5","key":"joi240036r13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub7","article-title":"Nicotine receptor partial agonists for smoking cessation.","volume":"2016","author":"Cahill","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"joi240036r14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1176\/appi.ajp.2013.12070919","article-title":"Adapting smoking cessation treatment according to initial response to precessation nicotine patch.","volume":"170","author":"Rose","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"11","key":"joi240036r15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1176\/appi.ajp.2014.13050595","article-title":"Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.","volume":"171","author":"Rose","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"6","key":"joi240036r16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3109\/07853890.2012.705016","article-title":"Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis.","volume":"44","author":"Mills","year":"2012","journal-title":"Ann Med"},{"issue":"11","key":"joi240036r17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/archgenpsychiatry.2009.142","article-title":"A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.","volume":"66","author":"Piper","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"22","key":"joi240036r18","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1001\/archinternmed.2009.426","article-title":"Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics.","volume":"169","author":"Smith","year":"2009","journal-title":"Arch Intern Med"},{"issue":"1","key":"joi240036r19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/JCP.0000000000000829","article-title":"Improvement of smoking abstinence rates with increased varenicline dosage: a propensity score-matched analysis.","volume":"38","author":"Karam-Hage","year":"2018","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"joi240036r20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamainternmed.2014.6916","article-title":"Increasing varenicline dose in smokers who do not respond to the standard dosage: a randomized clinical trial.","volume":"175","author":"Hajek","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"joi240036r21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.6004\/jnccn.2023.0013","article-title":"Smoking cessation, version 3.2022, NCCN clinical practice guidelines in oncology.","volume":"21","author":"Shields","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"joi240036r22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2020.25019","article-title":"Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task force recommendation statement.","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"key":"joi240036r23","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"joi240036r24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1037\/1064-1297.13.4.282","article-title":"Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.","volume":"13","author":"Cinciripini","year":"2005","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"joi240036r25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1037\/a0018168","article-title":"Effects of an intensive depression-focused intervention for smoking cessation in pregnancy.","volume":"78","author":"Cinciripini","year":"2010","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"joi240036r26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamapsychiatry.2013.678","article-title":"Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal.","volume":"70","author":"Cinciripini","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"joi240036r27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1037\/0893-164X.12.2.101","article-title":"Reliability and validity of a smoking timeline follow-back interview.","volume":"12","author":"Brown","year":"1998","journal-title":"Psychol Addict Behav"},{"issue":"6 pt 1","key":"joi240036r28","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1542\/peds.111.6.1318","article-title":"Smoking during pregnancy and newborn neurobehavior.","volume":"111","author":"Law","year":"2003","journal-title":"Pediatrics"},{"issue":"4","key":"joi240036r31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1191\/1740774505cn100oa","article-title":"Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis.","volume":"2","author":"Berry","year":"2005","journal-title":"Clin Trials"},{"issue":"4","key":"joi240036r34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/jama.2015.19284","article-title":"Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical trial.","volume":"315","author":"Baker","year":"2016","journal-title":"JAMA"},{"key":"joi240036r35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12916-016-0626-2","article-title":"Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial.","volume":"14","author":"Tulloch","year":"2016","journal-title":"BMC Med"},{"issue":"7","key":"joi240036r36","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/ntr\/ntab018","article-title":"Effectiveness of varenicline versus combination nicotine replacement therapy for smoking cessation: one-year outcomes in a smoking cessation clinic in Taiwan.","volume":"23","author":"Hsueh","year":"2021","journal-title":"Nicotine Tob Res"},{"issue":"3","key":"joi240036r37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.mayocp.2012.11.013","article-title":"Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice.","volume":"88","author":"Brose","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"joi240036r38","article-title":"Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.","volume":"9","author":"Lindson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"joi240036r39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3322\/caac.20031","article-title":"Treating tobacco dependence in a medical setting.","volume":"59","author":"Hurt","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"joi240036r40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2165\/00003495-200969100-00003","article-title":"Varenicline: a novel pharmacotherapy for smoking cessation.","volume":"69","author":"Jim\u00e9nez-Ruiz","year":"2009","journal-title":"Drugs"},{"key":"joi240036r30","volume-title":"Clinical Trials","author":"Pocock","year":"1983"},{"key":"joi240036r1","unstructured":"The Health Consequences of Smoking\u201350 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention; 2014. Accessed January 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK294315"},{"key":"joi240036r2","unstructured":"US Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General. 2020. Accessed January 2024. https:\/\/www.cdc.gov\/tobacco\/sgr\/2020-smoking-cessation\/index.html"},{"key":"joi240036r5","unstructured":"Fiore? MC, Jaen? CR, Baker? TB, . Treating tobacco use and dependence: 2008 update, clinical practice guideline. Updated March 4, 2015. Accessed June 13, 2022. https:\/\/wayback.archive-it.org\/7993\/20180125032208\/https:\/www.fda.gov\/ScienceResearch\/SpecialTopics\/CriticalPathInitiative\/CriticalPathOpportunitiesReports\/ucm077262.htm?"},{"key":"joi240036r29","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Updated November 27, 2017. Accessed August 25, 2021. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"joi240036r32","unstructured":"US Food and Drug Administration. Inovation\/stagnation: challenge and opportunity on the critical path to new medical products. Updated March 15, 20004. Accessed January 21, 2017. https:\/\/www.fda.gov\/downloads\/ScienceResearch\/SpecialTopics\/CriticalPathInitiative\/CriticalPathOpportunitiesReports\/UCM113411.pdf"},{"key":"joi240036r33","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Accessed January 26, 2022. https:\/\/www.R-project.org"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2818356\/jama_cinciripini_2024_oi_240036_1716416465.98349.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T17:59:29Z","timestamp":1716919169000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2818356"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":40,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,5,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.4183","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}